Janus Henderson Group PLC Ascendis Pharma A/S Transaction History

Janus Henderson Group PLC

$207 Billion
Q3 2025

A detailed history of Janus Henderson Group PLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Janus Henderson Group PLC holds 4,323,059 shares of ASND stock, worth $884 Million. This represents 0.41% of its overall portfolio holdings.

Number of Shares

4,323,059

Previous 4,427,792 2.37%

Holding current value

$884 Million

Previous $764 Million 12.46%

% of portfolio

0.41%

Previous 0.39%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$163.32 - $205.91 $17.1 Million - $21.6 Million	-104,733 Reduced 2.37%	4,323,059 $859 Million
Q2 2025 Aug 14, 2025	SELL	$137.41 - $179.1 $8.13 Million - $10.6 Million	-59,157 Reduced 1.32%	4,427,792 $764 Million
Q1 2025 May 15, 2025	BUY	$119.49 - $168.84 $12.7 Million - $18 Million	106,567 Added 2.43%	4,486,949 $699 Million
Q4 2024 Feb 14, 2025	BUY	$122.0 - $146.6 $23.6 Million - $28.4 Million	193,688 Added 4.63%	4,380,382 $603 Million
Q3 2024 Nov 14, 2024	BUY	$113.0 - $153.43 $30.3 Million - $41.1 Million	267,881 Added 6.84%	4,186,694 $625 Million
Q2 2024 Aug 14, 2024	BUY	$121.07 - $153.67 $18.4 Million - $23.3 Million	151,610 Added 4.02%	3,918,813 $534 Million
Q1 2024 May 15, 2024	SELL	$123.45 - $159.4 $28.1 Million - $36.3 Million	-227,582 Reduced 5.7%	3,767,203 $569 Million
Q4 2023 Feb 14, 2024	BUY	$86.1 - $127.36 $12.1 Million - $17.9 Million	140,252 Added 3.64%	3,994,785 $503 Million
Q3 2023 Nov 14, 2023	SELL	$86.5 - $103.97 $2.32 Million - $2.79 Million	-26,829 Reduced 0.69%	3,854,533 $361 Million
Q2 2023 Aug 14, 2023	BUY	$69.96 - $97.84 $24.4 Million - $34.1 Million	348,532 Added 9.87%	3,881,362 $346 Million
Q1 2023 May 15, 2023	SELL	$104.9 - $126.78 $11.7 Million - $14.1 Million	-111,125 Reduced 3.05%	3,532,830 $379 Million
Q4 2022 Feb 14, 2023	SELL	$99.42 - $131.97 $19.2 Million - $25.4 Million	-192,803 Reduced 5.03%	3,643,955 $445 Million
Q3 2022 Nov 14, 2022	SELL	$84.03 - $110.23 $2.06 Million - $2.7 Million	-24,501 Reduced 0.63%	3,836,758 $396 Million
Q2 2022 Aug 15, 2022	BUY	$78.08 - $117.61 $34.8 Million - $52.4 Million	445,732 Added 13.05%	3,861,259 $359 Million
Q1 2022 May 16, 2022	BUY	$102.18 - $135.75 $20 Million - $26.5 Million	195,562 Added 6.07%	3,415,527 $401 Million
Q4 2021 Feb 14, 2022	SELL	$127.1 - $169.66 $4.03 Million - $5.38 Million	-31,702 Reduced 0.97%	3,219,965 $433 Million
Q3 2021 Nov 16, 2021	BUY	$112.67 - $176.92 $14 Million - $22 Million	124,496 Added 3.98%	3,251,667 $518 Million
Q2 2021 Aug 16, 2021	SELL	$121.62 - $145.29 $4.88 Million - $5.83 Million	-40,141 Reduced 1.27%	3,127,171 $411 Million
Q1 2021 May 17, 2021	BUY	$124.92 - $173.33 $19.8 Million - $27.5 Million	158,483 Added 5.27%	3,167,312 $408 Million
Q4 2020 Feb 16, 2021	BUY	$151.2 - $182.76 $6.38 Million - $7.72 Million	42,223 Added 1.42%	3,008,829 $502 Million
Q3 2020 Nov 16, 2020	BUY	$134.29 - $154.32 $72.8 Million - $83.6 Million	541,918 Added 22.35%	2,966,606 $458 Million
Q2 2020 Aug 14, 2020	BUY	$110.87 - $156.01 $61.8 Million - $87 Million	557,498 Added 29.86%	2,424,688 $359 Million
Q1 2020 May 14, 2020	BUY	$97.01 - $145.11 $59.6 Million - $89.1 Million	614,186 Added 49.02%	1,867,190 $210 Million
Q4 2019 Feb 18, 2020	BUY	$91.45 - $139.12 $84.8 Million - $129 Million	926,762 Added 284.07%	1,253,004 $174 Million
Q3 2019 Nov 14, 2019	SELL	$95.8 - $118.9 $21.9 Million - $27.2 Million	-228,623 Reduced 41.2%	326,242 $31.4 Million
Q2 2017 Aug 17, 2017	BUY	N/A	554,865	554,865 $15.4 Million

Others Institutions Holding ASND

# of Institutions

317

Shares Held

65M

Call Options Held

476K

Put Options Held

142K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $11.4B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account

Janus Henderson Group PLC Ascendis Pharma A/S Transaction History